Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Sensipar / Mimpara (cinacalcet by Year
Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)
Amgen Sensipar / Mimpara (cinacalcet: -24.0% in FY2022, up 47.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
“|| Sensipar ® /Mimpara ™ | 10 | 54 | 64 | 84 | (24%)”
Source: Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Reported in Form 8-K Product Sales Detail by Product and Geographic Region.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | -24.0% | +47.0 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | -71.0% | -23.0 pts | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | -48.0% | +21.0 pts | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | -69.0% | -72.0 pts | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
| FY2018 | Dec 31, 2018 | 3.0% | – | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
Cite this data
StockData. (2026). Amgen Sensipar / Mimpara (cinacalcet (%), annual FY2018–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-sensipar-yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.